The randomized phase III QuANTUM-First study later evaluated the same backbone chemotherapy regimen in combination with quizartinib (40 mg orally daily) or placebo in adults up to 75 years of age with FLT3-ITD-mutated AML who were deemed suitable for intensive chemotherapy [37]. The gene discussed is FLT3; the disease is acute myeloid leukemia.